clinical trial · NCT07058012
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
NSABP Foundation Inc·phase2·recruiting·n = 79
Colo-rectal CancerCemiplimabcemiplimab plus fianlimabcemiplimab + REGN7075ctDNA testing
brief summary
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.
started
Apr 17, 2026
primary completion
Apr 17, 2029
completion
Jun 1, 2029
last updated
Jun 12, 2026
official title
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol